White Paper

Understanding eSource In The New Era Of Clinical Trial Design

Source: THREAD

By Jennifer Price, John Bunch, and Ryan Kennedy

document quality iStock-1199243271.jpg

Today’s clinical trial dashboards alert sponsors and sites to any developing data trends, highlight compliance issues, and provide insight to all study data, including lab and sensor data. This type of immediate alerting and reporting is available when collecting all data close to real time. The FDA defines electronic source data (eSource) as electronic source data initially recorded in an electronic format1. In decentralized clinical trials (DCTs) today, the participants do not visit the clinic or site for research-related data collection. The patient data is gathered electronically from a variety of sources that don’t need to be transcribed, verified, and double-checked. The participant may need to visit a lab or imaging center, and the resulting data from those facilities ends up in a DCT platform dashboard, in almost real-time.

This industry has been historically slow to adopt any change in existing methodology due to the complexity of adding new processes, new SOPs, providing training, and using a new technology. COVID-19 has pushed the industry into the digital age with the increased use of telehealth, virtual visits, data collected electronically by ePRO, electronic surveys and data provided directly by home health providers.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader